All In Biotech

Drug Trial Radar · NCT03401320

Evaluation of IM Letrozole ISM® Pharmacokinetics, Safety, and Tolerability in Healthy Post-menopausal Women (LISA-1)

A Phase I, Open Label, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Intramuscular Injections of Letrozole ISM® at Different Strengths in Voluntary Healthy Post Menopausal Women (LISA-1)

Last checked: Nov 20, 2026Latest source record: Dec 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

53

Actual

Start

Nov 6, 2017

Primary completion

May 17, 2024

Study completion May 17, 2024

Sponsor

Sponsor type
Industry
First posted
Jan 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase I, open label, dose escalation study designed to evaluate the pharmacokinetics, safety, and tolerability of single intramuscular injections of Letrozole ISM® at different strengths in voluntary healthy post menopausal women

Conditions

  • Healthy

Interventions

  • Letrozole ISMDrug

    2.5 mg Femara + single IM injection of 50-400 mg Letrozole ISM

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. λzTime frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
  2. CmaxTime frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
  3. Cmax/DTime frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
  4. tmaxTime frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
  5. tlagTime frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
  6. t½Time frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
  7. AUC∞Time frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
  8. AUC∞/DTime frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
  9. AUCextrapTime frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
  10. AUClastTime frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
  11. Vz/FTime frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)
  12. CL/FTime frame: Following single intramuscular administration of Letrozole ISM (Period 2, Day 1)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number 42001

    Prague, Czech Republic, Czechia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.